Biotech · Private company
ReGenTree, LLC
Track this companyFree. Adds ReGenTree, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- RGN-259Phase 3 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- RGN-259Phase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- RGN-259Phase 3 · Neurotrophic KeratopathyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2PHASE3 · COMPLETED · started Apr 11, 2023ClinicalTrials.gov NCT05555589 · fetched Nov 12, 2026
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3PHASE3 · COMPLETED · started May 24, 2019ClinicalTrials.gov NCT03937882 · fetched Nov 12, 2026
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2PHASE3 · COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02974907 · fetched Nov 12, 2026
- Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1PHASE3 · TERMINATED · started Sep 17, 2015ClinicalTrials.gov NCT02600429 · fetched Nov 12, 2026
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1PHASE2_PHASE3 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02597803 · fetched Nov 12, 2026